Nurix Therapeutics’ $160.4 Million Follow-on Offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters in the offering.

Nurix Therapeutics, Inc. completed its follow-on offering of 5,175,000 shares of common stock, including the full exercise by the underwriters of their option to purchase additional shares of common stock. The common stock is listed on the Nasdaq Global Market under the symbol “NRIX.”

J.P. Morgan Securities LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated, RBC Capital Markets, LLC, and Needham & Company, LLC acted as underwriters for the offering.

Based in San Francisco, California, Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders.

The Davis Polk corporate team included partners Alan F. Denenberg (Picture) and Emily Roberts and associates Jonathan Bye and Sherry Tan. The intellectual property and technology transactions team included partner David R. Bauer and associate Marisa Elena Bannon. The tax team included partner Michael Farber and associate Daniel L. Jose. Counsel Marcie A. Goldstein provided FINRA advice. Associate Allison Gunther provided 1940 Act advice. 

Involved fees earner: Marisa Elena Bannon – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Jonathan Bye – Davis Polk & Wardwell; Alan Denenberg – Davis Polk & Wardwell; Michael Farber – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Allison Gunther – Davis Polk & Wardwell; Daniel Jose – Davis Polk & Wardwell; Emily Roberts – Davis Polk & Wardwell; Sherry Tan – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: J.P. Morgan Securities LLC; Needham & Company; Piper Sandler; RBC Capital Markets; Stifel, Nicolaus & Company, Incorporated;

Author: Martina Bellini